Therapeutic dilemmas in treatment-resistant bipolar patients.
Bota
Robert G
RG
Sagduyu
Kemal
K
D000380:Agranulocytosis / Q000139:chemically induced* / Q000517:prevention & control; D018692:Antimanic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy*; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007258:Informed Consent / Q000331:legislation & jurisprudence; D007872:Legal Guardians; D011994:Recombinant Proteins
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003024:Clozapine; D000069585:Filgrastim